Net Income

With positive safety data for its novel UC drug, a €530M cash reserve, and a new commercial chief, Abivax is poised for a major market entry.

The homesite developer declared a $0.76 quarterly dividend, showcasing a resilient model that thrives by offering builders an asset-light land strategy.

A new Phase 2 trial is testing an inhaled version of a key IPF drug, aiming to reduce severe side effects and transform treatment for the fatal lung disease.

With a cash runway into 2027, the biotech firm prepares for critical data on its innovative bispecific antibody pipeline for hard-to-treat solid tumors.

Honored as a Top Woman to Watch, Christa Rugova is revolutionizing refrigerated logistics with innovative technology and inspiring a new generation of leaders.

A new study claims combining two cheap inflammation tests saves millions by cutting misdiagnoses, challenging years of cost-cutting medical advice.

A new CEO with a diverse background in aviation and automotive is set to steer the Thompson family's Texas energy and real estate empire into a new era.

A rapid sepsis test is proving its worth, slashing mortality rates and costs across diverse hospitals, offering a new blueprint for emergency care.

A 5-year pilot program will use advanced software to transform D.C.'s rooftop solar and EV chargers into a coordinated force for grid stability.

Amid rising storm damage and insurance demands, one AI startup is expanding nationally with tech that promises to transform how roofs are inspected and repaired.

Singapore's HomesToLife nearly doubles its net profit, fueled by a key acquisition and strong exports, defying global market headwinds that have hit rivals.

A new partnership aims to secure the growing army of non-human AI agents, promising rapid, secure deployment. But can it solve AI's identity crisis?

With over AUD$1M in sales from its first MDMA batch, Cortexa is validating Australia's pioneering move to legalize psychedelic-assisted therapy.

Facing financial pressure, Sleep Number launches its biggest product overhaul in a decade, hoping simpler choices and new tech can win back customers.

Niche's 2026 rankings reveal a major shift: Americans are choosing smaller, walkable communities that blend urban access with neighborhood charm.

Sydnexis's eye drop trial shows high efficacy in children 3-12, positioning it as a potential first-of-its-kind FDA-approved drug for myopia.

Tempest Therapeutics raises up to $6M in a critical financing deal to advance its CAR-T pipeline, balancing promising clinical data with financial pressures.

The bioconjugate CRDMO reports record profits and a $1.49B backlog, fueled by tech innovation, strategic acquisitions, and global expansion.

Nearly 200 Michigan lottery ticket workers secured record raises and benefits, signaling a major power shift in the national printing industry.

Lifecore Biomedical secures its third major manufacturing deal in five months, signaling a strategic shift that could reshape the aesthetics supply chain.